These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11558697)

  • 21. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA: approval of generic drug reversed by U.S. Court of Appeals.
    Beliveau S
    J Law Med Ethics; 2002; 30(1):120-2. PubMed ID: 11905262
    [No Abstract]   [Full Text] [Related]  

  • 23. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 25. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 26. The application of the patent laws to the drug approval process.
    Coggio BD; Cerrito FD
    Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
    [No Abstract]   [Full Text] [Related]  

  • 27. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 28. Toward allocative efficiency in the prescription drug industry.
    Guell RC; Fischbaum M
    Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patent laws: could changes enhance drug development?
    Mattes JA
    Arch Gen Psychiatry; 1997 Oct; 54(10):970. PubMed ID: 9337779
    [No Abstract]   [Full Text] [Related]  

  • 30. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 31. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Good drug, bad luck: business, regulatory issues can create obstacles for drug development.
    Goldman B
    J Natl Cancer Inst; 2004 Nov; 96(21):1573-4. PubMed ID: 15523084
    [No Abstract]   [Full Text] [Related]  

  • 33. U.S. patent law. Case probes what's fair game in the search for new drugs.
    Kintisch E
    Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
    [No Abstract]   [Full Text] [Related]  

  • 34. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 35. Value of pharmaceuticals: ensuring the future of research and development.
    Serajuddin HK; Serajuddin AT
    J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
    Barton JH; Emanuel EJ
    JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Countering delays in introduction of generic drugs.
    Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
    [No Abstract]   [Full Text] [Related]  

  • 38. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
    Eccleston LE
    Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
    [No Abstract]   [Full Text] [Related]  

  • 39. Patent term extension: an expensive and unnecessary giveaway.
    Gore A
    Health Aff (Millwood); 1982; 1(2):25-33. PubMed ID: 10621692
    [No Abstract]   [Full Text] [Related]  

  • 40. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.